Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

Journal of Virology

Volumn 76, Issue 11, 2002, Pages 5357-5368

  Chakrabarti, Bimal K ^a   Kong, Wing Pui ^a   Wu, Bei Yue ^a   Yang, Zhi Yong ^a   Friborg, Jacques ^a   Ling, Xu ^a   King, Steven R ^a   Montefiori, David C ^a   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; DNA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; OLIGOMER; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOGENICITY; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; CELL LINE, TRANSFORMED; FEMALE; GENE PRODUCTS, ENV; GENETIC VECTORS; GUINEA PIGS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, DNA;

EID: 0036096976     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.11.5357-5368.2002     Document Type: Article

References (57)

1. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
2. HIV-cell fusion. The viral mousetrap
3. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
4. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120
5. HIV vaccines. Viral envelope fails to deliver?
6. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies
7. Immunization with recombinant canarypox vectors expressing membraneanchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
8. The antibody response in HIV-1 infection
9. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
10. Core structure of gp41 from the HIV envelope glycoprotein
11. Tumorigenicity and lysis by natural killers
12. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
13. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket
14. A general model for the transmembrane proteins of HIV and other retroviruses
15. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
16. A new technique for the assay of infectivity of human adenovirus 5 DNA
17. HIV vaccines: Where we are and where we are going
18. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates
19. + T cell depletion in simian immunodeficiency virus-infected macaques
20. + T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques
21. Antigenic determinants on HIV-1 envelope glycoproteins: A dickens of a time with oligomer twist
22. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
23. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
24. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix
25. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
26. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
27. HIV vaccines. Back to primary school
28. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
29. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
30. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
31. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
32. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
33. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
34. Combination gene transfer to potentiate tumor regression
35. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
36. Antibody neutralization of HIV-1
37. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses
38. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA
39. A role for carbohydrates in immune evasion in AIDS
40. Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody
41. Regulation of HIV-1 transcription
42. Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression
43. Neutralization of HIV-1 by antibody
44. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
45. Analysis and sorting of T cells according to cytokine expression
46. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
47. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation
48. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
49. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120
50. Development of a preventive vaccine for Ebola virus infection in primates
51. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines
52. Atomic structure of the ectodomain from HIV-1 gp41
53. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide
54. Immunization for Ebola virus infection
55. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
56. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins
57. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1